THE NEED FOR STANDARDIZED PATHOLOGICAL STAGING OF PANCREATICODUODENECTOMY SPECIMENS

Citation
Ca. Staley et al., THE NEED FOR STANDARDIZED PATHOLOGICAL STAGING OF PANCREATICODUODENECTOMY SPECIMENS, Pancreas, 12(4), 1996, pp. 373-380
Citations number
40
Categorie Soggetti
Endocrynology & Metabolism",Physiology
Journal title
ISSN journal
08853177
Volume
12
Issue
4
Year of publication
1996
Pages
373 - 380
Database
ISI
SICI code
0885-3177(1996)12:4<373:TNFSPS>2.0.ZU;2-R
Abstract
A standardized method for pathologic evaluation and staging of pancrea ticoduodenectomy (PD) specimens is critical for accurate reporting of the number and location of lymph nodes and margins of resection. We ex amined the impact of standardized pathologic evaluation (SPE) of PD sp ecimens on the identification of regional lymph nodes and describe our detailed system for the pathologic analysis of the PD specimen, Forty consecutive patients underwent PD for histologically confirmed adenoc arcinoma of the pancreatic head between April 1990 and August 1993. Fi fteen consecutive specimens were examined before the introduction of t he SPE, and 25 consecutive specimens underwent SPE. Resection margins were evaluated by frozen-section analysis, and then the specimen was d ivided into six regions on an anatomic dissection board for lymph node identification. The 25 specimens examined according to the SPE had a significantly increased number of lymph nodes identified (P = 0.0001) compared with the 15 specimens examined without the SPE. Twelve of the 25 specimens contained positive lymph nodes, 6 of which were confined to the pancreaticoduodenal region. No positive nodes were found in th e periaortic region. There were no differences in pathologic variables between patients found to have negative and those with positive regio nal lymph nodes. SPE of PD specimens provides a method for improved ly mph node identification, ensures accurate prospective evaluation of ma rgins of resection, and provides a complete analysis of potentially im portant pathologic variables. We offer this system as a standardized m odel for groups engaged in protocol-based clinical research examining innovative multimodality treatment strategies for patients with resect able pancreatic cancer.